Table 4.

Antibody titers of three participants who had received only one or no dose of trivalent OPV.

Poliovirus Strain		Participant 1 (One Dose with tOPV)			Participant 2 (One Dose with tOPV)			Participant 3 (Unvaccinated with tOPV)
		Visit 1	Visit 2	Visit 3	Visit 1	Visit 2	Visit 3	Visit 1	Visit 2	Visit 3
	Sabin 1	128	>1024	>1024	8	>1024	>1024	<4	<4	16
Sabin	Sabin 2	128	>1024	>1024	8	512	512	<4	32	32
	Sabin 3	<4	64	128	8	>1024	>1024	<4	<4	128
	Mahoney (type 1)	8	>1024	>1024	4	1024	1024	<4	4	128
Virulent	MEF-1 (type 2)	64	>1024	>1024	4	>1024	>1024	<4	64	128
	Saukett (type 3)	<4	64	256	4	>1024	>1024	<4	<4	64
Type 2 VDPV	SV3128	64	>1024	>1024	4	>1024	1024	<4	32	64
	SV3130	64	>1024	>1024	4	>1024	>1024	<4	32	32
	11196	64	>1024	>1024	4	>1024	1024	<4	32	32
	11198	64	>1024	>1024	4	512	512	<4	32	32

Participants 1 and 2 had received one dose of tOPV, but participant 3 was unvaccinated with tOPV in childhood. Even one booster dose with cIPV was effective at enhancing antibody titers in participants 1 and 2, but participant 3 needed two doses of cIPV for a seropositive titer against all strains.